CRMD
CorMedix Inc.11.44
+0.11+0.97%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
901.35MP/E (TTM)
5.18Basic EPS (TTM)
2.21Dividend Yield
0%Recent Filings
8-K
Raises 2025 revenue guidance
CorMedix reported preliminary Q3 2025 net revenue exceeding $100 million, with DefenCath contributing over $85 million, fueled by robust LDO customer utilization and broader growth. The company raised full-year pro forma net revenue guidance to at least $375 million, incorporating the Melinta acquisition, while forecasting $30 million in operating synergies by year-end. Enrollment wrapped in the ReSPECT Phase III study for Rezzayo prophylaxis. Cash stood at $56 million, eyeing $100 million by December. Pro forma figures blend entities as if merged earlier.
8-K
CorMedix completes Melinta merger
CorMedix Inc. completed its merger with Melinta Therapeutics on August 29, 2025, acquiring seven marketed anti-infective products for $260 million cash and $40 million in stock, funded partly by a $150 million convertible notes offering. This bolsters CorMedix's hospital-focused portfolio, adding immediate revenue from established drugs like REZZAYO and MINOCIN while expanding the pipeline with a Phase III prophylaxis study for REZZAYO, potentially unlocking $200 million in peak sales if approved by 2029. Leadership shifts include Susan Blum as CFO, Elizabeth Hurlburt as COO, and Matthew David as Chief Business Officer, driving integration amid expected $35-45 million in annual synergies. Deal accretes EPS near-term, with pro forma 2025 revenues projected at $325-350 million.
8-K
CorMedix closes $150M notes offering
CorMedix Inc. closed its $150,000,000 private placement of 4.00% convertible senior notes due 2030 on August 12, 2025, exempt from registration under Section 4(a)(2) of the Securities Act. The notes carry an initial conversion rate of 74.2515 shares of common stock per $1,000 principal, governed by an indenture with U.S. Bank Trust Company. This capital raise bolsters the company's financial position. Use of proceeds remains undisclosed.
8-K
CorMedix acquires Melinta for $300M
CorMedix inked a merger deal on August 7, 2025, to snap up Melinta Therapeutics, bulking up its infectious disease lineup with seven marketed drugs like REZZAYO and MINOCIN for $300 million total—$260 million cash, $40 million in stock—funded partly by $150 million in 4% convertible notes due 2030. The move diversifies revenue streams in acute care, projecting pro forma 2025 sales of $305–$335 million while chasing $35–$45 million in annual synergies. Closing eyes September 2025, pending HSR clearance. Integration risks loom large.
10-Q
Q2 FY2025 results
CorMedix posted strong Q2 FY2025 results, with net sales hitting $39.7 million, up from $0.8 million a year earlier, fueled by DefenCath's inpatient and outpatient launches. Gross margins soared to 95.3% as volumes scaled, while operating income flipped to $19.5 million from a $15.3 million loss, thanks to revenue momentum offsetting steady expenses. Diluted EPS landed at $0.28, aligning with 71.9 million shares after anti-dilution from options. Cash swelled to $190.7 million, bolstered by $82.4 million from a public offering, supporting $49.7 million in operating cash flow. Post-quarter, CorMedix inked a $300 million deal for Melinta Therapeutics, blending $260 million cash and $40 million in stock, eyeing September close pending HSR clearance. Revenue hinges on dialysis contracts, yet securities litigation drags on.
AURX
Nuo Therapeutics, Inc.
2.00-0.15
BICX
BioCorRx Inc.
0.34-0.04
BIXT
Bioxytran, Inc.
0.07+0.00
CALC
CalciMedica, Inc.
5.22+0.59
CERS
Cerus Corporation
2.16+0.15
CNMD
CONMED Corporation
39.20-1.12
CORT
Corcept Therapeutics Incorporat
81.12-6.18
CRBP
Corbus Pharmaceuticals Holdings
8.66-0.82
CTXR
Citius Pharmaceuticals, Inc.
1.10+0.04
KRRO
Korro Bio, Inc.
8.22+0.26